MICROSCOPIC POLYANGIITIS
Clinical trials for MICROSCOPIC POLYANGIITIS explained in plain language.
Never miss a new study
Get alerted when new MICROSCOPIC POLYANGIITIS trials appear
Sign up with your email to follow new studies for MICROSCOPIC POLYANGIITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Smart dosing vs. scheduled shots: a fight to keep a serious autoimmune disease at bay
Disease control CompletedThis study tested two different long-term treatment plans for patients with a serious autoimmune disease called ANCA-associated vasculitis, who were already in remission. The goal was to see which plan was better at preventing the disease from flaring up again. One plan gave ritu…
Matched conditions: MICROSCOPIC POLYANGIITIS
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Cheaper copycat drugs put to the test for rare autoimmune disease
Disease control CompletedThis study compared newer, more affordable 'biosimilar' versions of the drug rituximab to the original version in patients with two rare autoimmune diseases (GPA and MPA). Researchers followed 201 Canadian patients for two years to see if the biosimilars worked as well and were a…
Matched conditions: MICROSCOPIC POLYANGIITIS
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC
-
Trial tests new strategy to prevent Flare-Ups of devastating autoimmune disease
Disease control CompletedThis study tested whether the drug rituximab is better than the standard drug azathioprine at keeping two severe autoimmune diseases (Wegener's granulomatosis and microscopic polyangiitis) in remission. It involved 117 adults whose disease was under control after initial treatmen…
Matched conditions: MICROSCOPIC POLYANGIITIS
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Mar 02, 2026 15:25 UTC
-
Alcoholism drug repurposed to fight pain and fatigue in rare autoimmune diseases
Symptom relief CompletedThis study tested whether a very low dose of an existing drug, naltrexone, could improve daily life for people with vasculitis, a group of rare autoimmune diseases that cause blood vessel inflammation. Sixty patients whose disease was stable but who still struggled with poor phys…
Matched conditions: MICROSCOPIC POLYANGIITIS
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Mar 30, 2026 14:33 UTC